Assessment of prolactin levels and sexual dysfunction in patients on long-acting risperidone ISM vs monthly paliperidone palmitate.
Por:
Labad J, Gálvez V, Gregorio M, Palacio A, Manzano Y, Gabernet R, Borràs M, Niubó M, Silles S, Toll A, Ruiz A, Ragull M and Hernández-Ribas R
Ahead of Print:
19 nov 2025
Resumen:
INTRODUCTION: Hyperprolactinaemia and sexual dysfunction are common adverse effects of antipsychotic drugs, particularly with dopamine D2 receptor antagonists. Long-acting injectables such as paliperidone palmitate (PP) and risperidone ISM may differ in their endocrine safety profiles, especially across sexes. We aimed to compare prolactin levels and clinically significant sexual dysfunction in patients treated with risperidone ISM vs monthly PP. METHODS: We conducted a cross-sectional study including 59 patients with psychotic disorders (27 on risperidone ISM, 32 on PP). Clinically significant hyperprolactinaemia was defined as prolactin levels above sex-specific thresholds along with hypogonadism and/or sexual dysfunction. The Arizona Sexual Experience Scale was used to assess sexual function. Hormonal assays included prolactin, testosterone, and oestradiol. Prolactin values were log-transformed for regression models. Multiple linear regression assessed predictors of prolactin, including treatment, sex, age, dose, co-treatment with aripiprazole or other antipsychotics, and sex-by-treatment interaction. An exploratory logistic regression examined predictors of clinically significant hyperprolactinemia (with either hypogonadism or sexual dysfunction). RESULTS: Women on PP showed significantly higher prolactin levels vs those on risperidone ISM (interaction between female sex and PP; p=0.002). Aripiprazole co-treatment was associated with lower prolactin levels (p=0.020). Clinically significant hyperprolactinaemia was present in 55.6% of the risperidone ISM group vs 68.8% of the PP group. The exploratory logistic regression model revealed no significant predictors of clinically significant hyperprolactinaemia. CONCLUSION: Risperidone ISM may be associated with a more favourable prolactin profile in women vs PP. Findings support the relevance of sex and adjunctive strategies in managing antipsychotic-induced endocrine side effects.
Filiaciones:
:
Department of Mental Health and Addictions, Consorci Sanitari del Maresme, Hospital Universitari de Mataró, Universitat Autònoma de Barcelona, Mataró, Spain
Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain
Gálvez V:
Department of Mental Health and Addictions, Consorci Sanitari del Maresme, Hospital Universitari de Mataró, Universitat Autònoma de Barcelona, Mataró, Spain
Gregorio M:
Department of Mental Health and Addictions, Consorci Sanitari del Maresme, Hospital Universitari de Mataró, Universitat Autònoma de Barcelona, Mataró, Spain
Palacio A:
Department of Mental Health and Addictions, Consorci Sanitari del Maresme, Hospital Universitari de Mataró, Universitat Autònoma de Barcelona, Mataró, Spain
Manzano Y:
Department of Mental Health and Addictions, Consorci Sanitari del Maresme, Hospital Universitari de Mataró, Universitat Autònoma de Barcelona, Mataró, Spain
Gabernet R:
Department of Mental Health and Addictions, Consorci Sanitari del Maresme, Hospital Universitari de Mataró, Universitat Autònoma de Barcelona, Mataró, Spain
Borràs M:
Department of Mental Health and Addictions, Consorci Sanitari del Maresme, Hospital Universitari de Mataró, Universitat Autònoma de Barcelona, Mataró, Spain
Niubó M:
Department of Mental Health and Addictions, Consorci Sanitari del Maresme, Hospital Universitari de Mataró, Universitat Autònoma de Barcelona, Mataró, Spain
Silles S:
Department of Mental Health and Addictions, Consorci Sanitari del Maresme, Hospital Universitari de Mataró, Universitat Autònoma de Barcelona, Mataró, Spain
Toll A:
Department of Mental Health and Addictions, Consorci Sanitari del Maresme, Hospital Universitari de Mataró, Universitat Autònoma de Barcelona, Mataró, Spain
Ruiz A:
Laboratory Department, Laboratori de Referència de Catalunya, Mataró, Spain
Ragull M:
Department of Mental Health and Addictions, Consorci Sanitari del Maresme, Hospital Universitari de Mataró, Universitat Autònoma de Barcelona, Mataró, Spain
Hernández-Ribas R:
Department of Mental Health and Addictions, Consorci Sanitari del Maresme, Hospital Universitari de Mataró, Universitat Autònoma de Barcelona, Mataró, Spain
|